Olav Engebraaten

Oslo, Norway

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 60 publications

Spatial organization of the tumor-immune microenvironment in ER-positive breast cancer: remodeling during treatment and associations with clinical response.

Spatial organization of the tumor-immune microenvironment in ER-positive breast cancer: remodeling during treatment and associations with clinical response.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE.

Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE.

Journal: BMJ open

Published: August 27, 2025

High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy.

High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy.

Journal: Breast cancer research : BCR

Published: March 23, 2025

Chemoresistant tumor cell secretome potentiates immune suppression in triple negative breast cancer.

Chemoresistant tumor cell secretome potentiates immune suppression in triple negative breast cancer.

Journal: Breast cancer research : BCR

Published: March 03, 2025

The harmonized activities of HER2-HER3 heterodimer and deacetylated FOXA1 evade hormone response by regulating FOXA1 chromatin binding.

The harmonized activities of HER2-HER3 heterodimer and deacetylated FOXA1 evade hormone response by regulating FOXA1 chromatin binding.

Journal: Nucleic acids research

Published: January 03, 2025

The mechanisms of HER2 targeted ADCs are dependent on Rab GTPases.

The mechanisms of HER2 targeted ADCs are dependent on Rab GTPases.

Journal: Therapeutic advances in medical oncology

Published: August 27, 2024

The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy.

The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy.

Journal: British journal of cancer

Published: May 10, 2024

Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer-a prospective national multicentre study (EMIT-1).

Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer-a prospective national multicentre study (EMIT-1).

Journal: ESMO open

Published: January 18, 2024

An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer.

An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer.

Journal: Molecular oncology

Published: July 11, 2023

Corrigendum to "Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft", [Journal of Control Release, 293 (2019) 183-192].

Corrigendum to "Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft", [Journal of Control Release, 293 (2019) 183-192].

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: July 06, 2022

High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer.

High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer.

Journal: PloS one

Published: July 04, 2022

Liver X receptors induce antiproliferative effects in basal-like breast cancer.

Liver X receptors induce antiproliferative effects in basal-like breast cancer.

Journal: Molecular oncology

Published: June 28, 2022

Showing 1-12 of 60

Last Updated: 09/26/2026